Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $157000.0.

  • Benitec Biopharma's Other Accumulated Expenses rose 9873.42% to $157000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $157000.0, marking a year-over-year increase of 9873.42%. This contributed to the annual value of $138000.0 for FY2024, which is 10000.0% up from last year.
  • As of Q1 2025, Benitec Biopharma's Other Accumulated Expenses stood at $157000.0, which was up 9873.42% from $92000.0 recorded in Q4 2024.
  • In the past 5 years, Benitec Biopharma's Other Accumulated Expenses ranged from a high of $223000.0 in Q4 2021 and a low of $36000.0 during Q1 2023
  • Over the past 5 years, Benitec Biopharma's median Other Accumulated Expenses value was $79000.0 (recorded in 2024), while the average stood at $96764.7.
  • As far as peak fluctuations go, Benitec Biopharma's Other Accumulated Expenses skyrocketed by 14505.49% in 2021, and later plummeted by 8161.43% in 2022.
  • Over the past 5 years, Benitec Biopharma's Other Accumulated Expenses (Quarter) stood at $223000.0 in 2021, then tumbled by 81.61% to $41000.0 in 2022, then surged by 80.49% to $74000.0 in 2023, then increased by 24.32% to $92000.0 in 2024, then soared by 70.65% to $157000.0 in 2025.
  • Its Other Accumulated Expenses was $157000.0 in Q1 2025, compared to $92000.0 in Q4 2024 and $59000.0 in Q3 2024.